


Cost - Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate - Alone Strategies in High - Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide

Teriparatide is a costly drug for the treatment of osteoporosis.

In the US, market exclusivity for brand teriparatide expired in August 2019.

We examined the potential health economic impact of the availability of generic/biosimilar teriparatide, using Markov microsimulation models.



Among high-risk osteoporotic women, sequential teriparatide/alendronate would not be cost - effective unless the cost of generic/biosimilar teriparatide were heavily discounted.

Reference: Mori et al., JBMR Plus. 2019 Nov; 3(11): e10233

Contact: Takahiro Mori, MD MSHS PhD, Associate Professor at the University of Tsukuba

Collaboration with UCLA